CDG UPDATES

CDG UPDATES

Tigermed Lists on the Hong Kong Stock Exchange

发布者:CDG Capital    时间:2020年08月28日

HANGZHOU TIGERMED CONSULTING CO., LTD. (“Tigermed”; Stock code: 300347.SZ/3347.HK) announced its listing on the Main Board of the Hong Kong Stock Exchange today

Based on the offer price of HK$100 per share and approximately 107 million H-shares issued (subject to the Over-allotment Option), the net proceeds to be received by the Company, after deduction of the underwriting commission and other estimated expenses payable by the Company in connection with the offering, are estimated to be about HK$10,272.5 million (assuming the Over-allotment Option is not exercised). The funds will be used to expand and enhance Tigermed’s service offerings and capabilities across clinical trial solutions services and clinical-related services, to fund potential acquisitions and minority investments, to develop and implement technologies to enhance the quality and efficiency of Tigermed’s comprehensive service offerings, and to boost working capital.

The successful listing on the Hong Kong Stock Exchange marks the landing of Tigermed’s “A + H” dual-capital platform. It will provide strong capital support for the Company’s future global operation and business expansions, which will accelerate the pace of the Company’s internationalization strategy. Moreover, this will also lay a solid foundation for the Company to further consolidate and expand its integrated biopharmaceutical R & D service platform and expedite the global development of innovative drugs.

 

上一篇下一篇

©️ 2020 All Rights Reserved 晨岭资本有限公司 版权所有 粤ICP备2020113789号